These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 20380933)

  • 41. Diagnosis of colorectal hepatic metastases: comparison of contrast-enhanced CT, contrast-enhanced US, superparamagnetic iron oxide-enhanced MRI, and gadoxetic acid-enhanced MRI.
    Muhi A; Ichikawa T; Motosugi U; Sou H; Nakajima H; Sano K; Sano M; Kato S; Kitamura T; Fatima Z; Fukushima K; Iino H; Mori Y; Fujii H; Araki T
    J Magn Reson Imaging; 2011 Aug; 34(2):326-35. PubMed ID: 21780227
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT.
    Baek CK; Choi JY; Kim KA; Park MS; Lim JS; Chung YE; Kim MJ; Kim KW
    Clin Radiol; 2012 Feb; 67(2):148-56. PubMed ID: 21920517
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging.
    Haradome H; Grazioli L; Tinti R; Morone M; Motosugi U; Sano K; Ichikawa T; Kwee TC; Colagrande S
    J Magn Reson Imaging; 2011 Jul; 34(1):69-78. PubMed ID: 21598343
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Can the patient with cirrhosis be imaged for hepatocellular carcinoma without gadolinium?: Comparison of combined T2-weighted, T2*-weighted, and diffusion-weighted MRI with gadolinium-enhanced MRI using liver explantation standard.
    Hardie AD; Kizziah MK; Rissing MS
    J Comput Assist Tomogr; 2011; 35(6):711-5. PubMed ID: 22082541
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
    Park MJ; Kim YK; Lee MH; Lee JH
    Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hypervascular hepatocellular carcinoma in the cirrhotic liver: diffusion-weighted imaging versus superparamagnetic iron oxide-enhanced MRI.
    Chung J; Yu JS; Kim DJ; Chung JJ; Kim JH; Kim KW
    Magn Reson Imaging; 2011 Nov; 29(9):1235-43. PubMed ID: 21907517
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Usefulness of combining sequentially acquired gadobenate dimeglumine-enhanced magnetic resonance imaging and resovist-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: comparison with computed tomography hepatic arteriography and computed tomography arterioportography using 16-slice multidetector computed tomography.
    Kim YK; Kwak HS; Han YM; Kim CS
    J Comput Assist Tomogr; 2007; 31(5):702-11. PubMed ID: 17895780
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas.
    Yoon JH; Lee EJ; Cha SS; Han SS; Choi SJ; Juhn JR; Kim MH; Lee YJ; Park SJ
    J Vasc Interv Radiol; 2010 Mar; 21(3):348-56. PubMed ID: 20116285
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Additional value of SPIO-enhanced MR imaging for the noninvasive imaging diagnosis of hepatocellular carcinoma in cirrhotic liver.
    Yoo HJ; Lee JM; Lee JY; Kim SH; Kim SJ; Han JK; Choi BI
    Invest Radiol; 2009 Dec; 44(12):800-7. PubMed ID: 19838119
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging.
    Kim MJ; Kim JH; Lim JS; Oh YT; Chung JJ; Choi JS; Lee WJ; Kim KW
    J Magn Reson Imaging; 2004 Oct; 20(4):612-21. PubMed ID: 15390224
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The usefulness of gadoxetic acid-enhanced dynamic magnetic resonance imaging in hepatocellular carcinoma: toward improved staging.
    Choi SH; Byun JH; Kwon HJ; Ha HI; Lee SJ; Kim SY; Won HJ; Kim PN
    Ann Surg Oncol; 2015 Mar; 22(3):819-25. PubMed ID: 25201507
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging.
    Lutz AM; Willmann JK; Goepfert K; Marincek B; Weishaupt D
    Radiology; 2005 Nov; 237(2):520-8. PubMed ID: 16192317
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Use of SPIO-enhanced T1- and T2-weighted images for the differentiation of liver lesions: an ROC analysis].
    Stroszczynski C; Gaffke G; Gretschel S; Rambow A; Jost D; Schlecht I; Schneider U; Schicke B; Hohenberger P; Gebauer B; Felix R
    Rofo; 2003 Oct; 175(10):1368-75. PubMed ID: 14556106
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study.
    Tsurusaki M; Sofue K; Isoda H; Okada M; Kitajima K; Murakami T
    J Gastroenterol; 2016 Jan; 51(1):71-9. PubMed ID: 26130441
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection of hepatocellular carcinoma with ferucarbotran (resovist)-enhanced breath-hold MR imaging: feasibility of 10 minute-delayed images.
    Saito K; Shindo H; Ozuki T; Ishikawa A; Kotake F; Shimazaki Y; Abe K
    Magn Reson Med Sci; 2008; 7(3):123-30. PubMed ID: 18827455
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Focal liver lesions. A comparison between magnetic resonance under base conditions and after a superparamagentic contrast medium].
    Finazzo M; Midiri M; Gallo C; Bartolotta TV; Luca A
    Radiol Med; 1998 Jun; 95(6):599-607. PubMed ID: 9717542
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is gadoxetate disodium-enhanced MRI useful for detecting local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy?
    Watanabe H; Kanematsu M; Goshima S; Yoshida M; Kawada H; Kondo H; Moriyama N
    AJR Am J Roentgenol; 2012 Mar; 198(3):589-95. PubMed ID: 22357997
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine.
    Park G; Kim YK; Kim CS; Yu HC; Hwang SB
    Br J Radiol; 2010 Dec; 83(996):1010-6. PubMed ID: 20682591
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging.
    Sano K; Ichikawa T; Motosugi U; Sou H; Muhi AM; Matsuda M; Nakano M; Sakamoto M; Nakazawa T; Asakawa M; Fujii H; Kitamura T; Enomoto N; Araki T
    Radiology; 2011 Dec; 261(3):834-44. PubMed ID: 21998047
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Detection of small hepatocellular carcinoma: intraindividual comparison of gadoxetic acid-enhanced MRI at 3.0 and 1.5 T.
    Kim YK; Kim CS; Han YM; Yu HC; Choi D
    Invest Radiol; 2011 Jun; 46(6):383-9. PubMed ID: 21467946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.